Anileridine

Anileridine (trade name: Leritine) is a synthetic analgesic drug^[2] and is a member of the piperidine class of analgesic agents^[3] developed by Merck & Co. in the 1950s.^[4] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

Anileridine

Clinical data
Trade names	Leritine
AHFS/Drugs.com	Monograph
Routes of administration	Tablets, injection
ATC code	N01AH05 (WHO)
Legal status
Legal status	AU: S8 (Controlled drug) BR: Class A1 (Narcotic drugs)[1] CA: Schedule I DE: Anlage I (Authorized scientific use only) US: Schedule II
Pharmacokinetic data
Protein binding	> 95%
Metabolism	Hepatic
Identifiers
IUPAC name Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
CAS Number	144-14-9 Y
PubChem CID	8944
IUPHAR/BPS	7115
DrugBank	DB00913 Y
ChemSpider	8600 Y
UNII	71Q1A3O279
KEGG	D02941 Y
ChEBI	CHEBI:61203 Y
ChEMBL	ChEMBL1201347 N
CompTox Dashboard (EPA)	DTXSID8022610
Chemical and physical data
Formula	C22H28N2O2
Molar mass	352.478 g·mol−1
3D model (JSmol)	Interactive image
Melting point	83 °C (181 °F)
SMILES O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3
InChI InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 Y Key:LKYQLAWMNBFNJT-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Anileridine is no longer manufactured in the US or Canada.^[5] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate.^[6] It is also under international control per UN treaties.

Administration

As tablets or injection.^[7]

Pharmacokinetics

Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.^[8] It is mostly metabolized by the liver.

See also

• Pheneridine